VEGF gene polymorphism association with diabetic foot ulcer

Diabetes Research and Clinical Practice

Volumn 93, Issue 2, 2011, Pages 215-219

  Amoli, Mahsa M ^a   Hasani Ranjbar, Shirin ^a   Roohipour, Nahid ^a   Sayahpour, Forough A ^a   Amiri, Parvin ^a   Zahedi, Parisa ^a   Mehrab Mohseni, Mahdie ^b   Heshmat, Ramin ^a   Larijani, Bagher ^a   Tavakkoly Bazzaz, Javad ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetic foot ulcer; Polymorphism; VEGF

Indexed keywords

ALANINE; CYSTEINE; THREONINE;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC FOOT; ETHNIC GROUP; FEMALE; GENE; GENE FREQUENCY; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE;

ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; DIABETIC FOOT; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IRAN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80051571344     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.04.016     Document Type: Article

References (39)

1. Boulton A.J. The diabetic foot: grand overview, epidemiology and pathogenesis. Diabetes Metab Res Rev 2008, 24(Suppl. 1):S3-S6.
2. Rico T., Green J., Kirsner R.S. Vascular endothelial growth factor delivery via gene therapy for diabetic wounds: first steps. J Invest Dermatol 2009, 129(9):2084.
3. Boulton A.J., Armstrong D.G., Albert S.F., Frykberg R.G., Hellman R., Kirkman M.S., et al. Task Force of the Foot Care Interest Group of the American Diabetes Association. Comprehensive foot examination and risk assessment. Endocr Pract 2008, 14(5):576-583.
4. Setacci C., de Donato G., Setacci F., Chisci E. Diabetic patients: epidemiology and global impact. J Cardiovasc Surg (Torino) 2009, 50(3):263-273.
5. Aiello L.P., Wong J.S. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 2000, 77:S113-S119.
6. Caldwell R.B., Bartoli M., Behzadian M.A., El-Remessy A.E., Al-Shabrawey M., Platt D.H., et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003, 19:442-455.
7. Khamaisi M., Schrijvers B.F., De Vriese A.S., Raz I., Flyvbjerg A. The emerging role of VEGF in diabetic kidney disease. Nephrol Dial Transplant 2003, 18:1427-1430.
8. Leinninger G.M., Vincent A.M., Feldman E.L. The role of growth factors in diabetic peripheral neuropathy. J Peripher Nerv Syst 2004, 9:26-53.
9. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
10. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039.
11. Unemori E.N., Ferrara N., Bauer E.A., Amento E.P. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992, 153:557-562.
12. Mu H., Zhang X.M., Liu J.J., Dong L., Feng Z.L. Effect of high glucose concentration on VEGF and PEDF expression in cultured retinal Müller cells. Mol Biol Rep 2009, 36(8):2147-2151. 24.
13. Li J., Zhang Y.P., Kirsner R.S. Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc Res Tech 2003, 60(1):107-114.
14. Seaquist E.R., Goetz F.C., Rich S., Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989, 320:1161-1165.
15. Borch-Johnsen K., Norgaard K., Hommel E., Mathiesen E.R., Jensen J.S., Deckert T., et al. Is diabetic nephropathy an inherited complication?. Kidney Int 1992, 41:719-722.
16. Earle K., Walker J., Hill C., Viberti G. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N Engl J Med 1992, 326:673-677.
17. Quinn M., Angelico M.C., Warram J.H., Krolewski A.S. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 1996, 39:940-945.
18. Diabetes Control and Complications Trial (DCCT) Research Group Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes 1997, 46:1829-1839.
19. Pettitt D.J., Saad M.F., Bennett P.H., Nelson R.G., Knowler W.C. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990, 33:438-443.
20. Faronato P.P., Maioli M., Tonolo G., Brocco E., Noventa F., Piarulli F., et al. Clustering of albumin excretion rate abnormalities in Caucasian patients with NIDDM. The Italian NIDDM Nephropathy Study Group. Diabetologia 1997, 40:816-823.
21. Canani L.H., Gerchman F., Gross J.L. Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. Diabetes 1999, 48:909-913.
22. Abbott C.A., Carrington A.L., Ashe H., Bath S., Every L.C., Griffiths J., et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002, 19(5):377-384.
23. Onen I.H., Konac E., Eroglu M., Guneri C., Biri H., Ekmekci A. No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population. Mol Biol Rep 2008, 35(1):17-22.
24. Sfar S., Saad H., Mosbah F., Chouchane L. Combined effects of the angiogenic genes polymorphisms on prostate cancer susceptibility and aggressiveness. Mol Biol Rep 2009, 36(1):37-45.
25. Marsh S., Nakhoul F.M., Skorecki K., Rubin A., Miller B.P., Leibu R., et al. Hypoxic induction of vascular endothelial growth factor is markedly decreased in diabetic individuals who do not develop retinopathy. Diabetes Care 2000, 23:1375-1380.
26. Tavakkoly-Bazzaz J., Amoli M.M., Pravica V., Chandrasecaran R., Boulton A.J., Larijani B., et al. VEGF gene polymorphism association with diabetic neuropathy. Mol Biol Rep 2010, 37(7):3625-3630.
27. Nakamura S., Iwasaki N., Funatsu H., Kitano S., Iwamoto Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2009, 247(1):21-26.
28. Feldman E.L., Stevens M.J., Thomas P.K., Brown M.B., Canal N., Greene D.A. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994, 17:1281-1289.
29. Senger D.R., Connolly D.T., Van de W.L., Feder J., Dvorak H.F. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990, 50:1774-1778.
30. Stehouwer C.D., Lambert J., Donker A.J., van Hinsbergh V.W. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997, 34:55-68.
31. DCCT Research Group Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes 1988, 37(4):476-481.
32. Wagner F.W. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle 1981, 2(2):64-122.
33. Renner W., Kotschan 5, Hoffmann C., Obermayer-Pietsch B., Pilger E.A. common 936C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000, 37:443-448.
34. Watson C.J., Webb N.J., Bottomley M.J., Brenchley P.E. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000, 12:1232-1235.
35. Shahbazi M., Fryer M., Pravica V., Brogan I.J., Ramsay H.M., Hutchinson I.V., et al. Vascular endothelial growth factor gene polymorph isms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002, 13:260-264.
36. Wang T., Hu K., Ren J., Zhu Q., Wu G., Peng G. Polymorphism of VEGF-2578C/A associated with the risk and aggressiveness of nasopharyngeal carcinoma in a Chinese population. Mol Biol Rep 2010, 37(1):59-65.
37. Lin T.H., Wang C.L., Su H.M., Hsu P.C., Juo S.H., Voon W.C., et al. Functional vascular endothelial growth factor gene polymorphisms and diabetes: effect on coronary collaterals in patients with significant coronary artery disease. Clin Chim Acta 2010, 411(21-22):1688-1693.
38. Brem H., Kodra A., Golinko M.S., Entero H., Stojadinovic O., Wang V.M., et al. Mechanism of sustained release of vascular endothelial growth factor in accelerating experimental diabetic healing. J Invest Dermatol 2009, 129(9):2275-2287.
39. Hanft J.R., Pollak R.A., Barbul A., van Gils C., Kwon P.S., Gray S.M., et al. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. J Wound Care 2008, 17(1):30-32. 34-7.